Summary
65 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 13 EUR is left as net profit.
- It earns 9.1 EUR a year on every 100 EUR of invested capital.
- It has raised its dividend 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 3.5% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 31.4 EUR for 1 EUR of yearly profit. Over the last five years it was 24.9 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 5.6% a year over 5 years. Over the last 3 years it fell by 3.5% a year. For the next fiscal year analysts expect revenue to grow by 4.7%.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 64 EUR
- Research and development 1.5 EUR
- Sales and administration 14 EUR
- Taxes and other 8.1 EUR
- Net profit 13 EUR
Net profit, industry median (Chemicals - Specialty) 5.9 EUR
Out of every 100 EUR of revenue, 13 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 11.3 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.94%
- Paid out of profit
- 61%
- Raised in a row
- 6 years
You receive 3.36 € per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail